Stelis Biopharma, a wholly owned subsidiary of Strides Arcolab today announced the ground-breaking for construction of its customized, multi-product, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia's premier park and ecosystem for industrial and healthcare biotechnology.
''Stelis is pleased yo commence work on its flagship biopharmaceutical facility in Malaysia. With its strong commitment to bio-economy, attractive incentives, quality infrastructure and enabling ecosystem, we are confident of making this our bio-manufacturing hub for regional and global markets,'' said Joe Thomas, CEO of Stelis Biopharma, on the occasion.
Shares of the company gained Rs 15.05, or 1.65%, to settle at Rs 928. The total volume of shares traded was 116,995 at the BSE (Wednesday).